Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of oral N-acetyl-D-mannosamine (ManNAc) for the treatment of individuals with GNE myopathy

Trial Profile

A clinical study of oral N-acetyl-D-mannosamine (ManNAc) for the treatment of individuals with GNE myopathy

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2018

At a glance

  • Drugs N acetyl D mannosamine (Primary)
  • Indications Nonaka distal myopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Sep 2018 New trial record
    • 15 Aug 2018 According to a Leadiant Biosciences media release, National Human Genome Research Institute (NHGRI) is the sponsorer of the study. Dr. Nuria Carrillo from NHGRI and Dr. Anthony Amato from Brigham and Women's Hospital are the co- principal investigators of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top